
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1074 | 981 | 1074 | 1099 | 1191 | 1734 |
Fund Return | 7.41% | -1.87% | 7.41% | 3.2% | 3.56% | 5.66% |
Place in category | 235 | 279 | 235 | 282 | 204 | 83 |
% in Category | 56 | 62 | 56 | 67 | 54 | 35 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Multi Asset Fund IV R3 GBP Acc | 1.22B | 3.93 | 8.35 | 7.32 | ||
International Index Tracking Fund 2 | 921.35M | 0.53 | 12.05 | 11.82 | ||
International Index Tracking Fund 1 | 921.35M | 19.84 | 8.41 | 11.86 | ||
UK Equity Income Fund 2 GBP Acc | 743.27M | 4.65 | 5.50 | 5.71 | ||
UK Equity Income Fund 1 GBP Inc | 743.27M | 4.64 | 5.31 | 5.52 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
GB00B2PLJH12 | 2.05B | 6.61 | 10.97 | 7.28 | ||
TB Evenlode Income B Income | 3.01B | 3.59 | 6.59 | 7.84 | ||
UK Equity Income Fund Retail Accumu | 114.72M | 1.63 | 8.03 | 5.61 | ||
UK Equity Income Fund Z Accumulatio | 625.46M | 3.11 | 8.46 | 6.78 | ||
UK Equity Income Fund Z Income GBP | 625.65M | 3.11 | 8.47 | 6.79 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Shell | GB00BP6MXD84 | 7.31 | 30.64 | +0.59% | |
Unilever | GB00B10RZP78 | 6.25 | 54.80 | +1.41% | |
National Grid | GB00BDR05C01 | 5.32 | 929.80 | +1.09% | |
AstraZeneca | GB0009895292 | 4.90 | 12,072.0 | +0.37% | |
Lloyds Banking | GB0008706128 | 4.71 | 70.92 | -2.50% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Neutral | Buy | Buy |
Technical Indicators | Sell | Strong Buy | Strong Buy |
Summary | Neutral | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review